Internal Med Medical News about Papillomavirus Vaccines Gardasil

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

ACIP Supports 'Permissive Use,' But Not Routine Use, of Gardasil in Males
American Family Physician, 10/29/09

Mitchell D – The CDC's Advisory Committee on Immunization Practices, or ACIP, has recommended against the routine use of quadrivalent human papillomavirus, or HPV, vaccine to prevent genital warts in boys and young men. Instead, the committee voted during its Oct. 21–22 meeting in Atlanta to support the "permissive use" of Gardasil, Merck & Co. Inc.'s quadrivalent HPV vaccine, leaving decisions on whether to immunize males ages 9–26 years who request the vaccine up to their health care professionals. However, the committee did recommend that the CDC provide funding for administration of the vaccine through the agency's Vaccines for Children, or VFC, program for males who want to receive it. Gardasil has not been shown to prevent cancer in males, and some ACIP members at the meeting viewed warts primarily as a cosmetic or fairly benign problem that – except in some rare instances – was less serious than other vaccine–preventable diseases.

<< Previous
A double-blind placebo-controlled study of the efficacy and...

Next >>
Genetic and environmental effects on the continuity of...